ARYx Therapeutics, Inc. (ARYX)

Market Cap	33.00
Revenue (ttm)	n/a
Net Income	-18.33M
EPS	-0.59
Shares Out	33.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,090
Open	0.000001
Previous Close	0.000001
Day's Range	0.000001 - 0.000001
52-Week Range	0.000001 - 0.000001
Beta	536.24
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ARYx Therapeutics

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 16
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARYX

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 11, 2026

Data Sources Report a data error